SEATTLE, April 29, 2013 /PRNewswire/ -- Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced an agreement for NutraGenesis, a diversified nutraceutical product marketing company, to sell and market Plandai's patented Phytofare extracts under a 3-year distribution agreement.
The agreement grants NutraGenesis (http://nutragenesis.com) exclusive rights to sell and market Phytofare to its client base in North America. NutraGenesis will apply its marketing and distribution expertise to provide Phytofare extracts to a growing number of potential customers.
In published USDA studies, Plandai's proprietary plant extracts, including Phytofare Catechin Extract, Phytofare Glucoside Complex and Phytofare Carotenoid Extract, have shown to have improved bioavailability the degree to which a substance becomes available to the target tissue after administration of between 60-80%, far exceeding anything available today. Superior levels of bioavailability simply mean that the body can actually receive the benefits promised on the product label.
The Company believes that its technology is the foundation for creating an entirely new family of drugs that can treat a multitude of diseases and conditions safely and affordably using naturally-derived extracts.
"The agreement with NutraGenesis demonstrates the faith they have in Phytofare, and we expect NutraGenesis to play a key role in our global distribution strategy," said Callum Baylis-Duffield, Vice-President and Global Director, Marketing Sales for Plandai Biotechnology. "This is just one of a number of regional distribution relationships that we expect to announce that will introduce Phytofare to customers in a variety of markets worldwide."
Suzanne McNeary, President of NutraGenesis, commented, "We are pleased to secure this agreement for Phytofare extracts and look forward to initiating our distribution efforts. NutraGenesis believes that Plandai's extracts will be well-received by our client base in North America."
About Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandai's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandai is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
SOURCE Plandai Biotechnology, Inc.